Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial


Disclosures: None

Contributions: U.P. conceptualized the study design, helped with interpretation of data, and ensured compliance with the regulatory requirements for the clinical trial; R.S.M. contributed to the interpretation of data and wrote the manuscript; R.B. contributed to the data analysis and figures and wrote the statistical section of the manuscript; J.C. provided clinical data; B.C.V. helped with correlatives; J.K. performed the pharmacokinetic analysis of busulfan; S.A., A.M.A., P.A., G.A., Q.B., S.O.C, C.M.H, J.S.I, R.J., P.K., I.K., D.M., J.J.M., Y.N., A.O., B.O., S.P., K.R., M.H.Q., N.S., and E.J.S., enrolled patients in the study and monitored clinical responses; and R.E.C. and B.S.A. enrolled patients in the study, monitored patients’ clinical responses, and conceptualized the study design.